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Abstract We analysed the expression of CD95/CD95L in two
widely used models for studying the cellular effects of chronic
infection with human immunodeficiency virus type 1 (HIV-1), i.e.
ACH-2 cells, derived from the lymphocytic cell line A301, and
U1, derived from monocytic U937 cells. A301 and ACH-2
mounted the same amount of plasma membrane CD95, while U1
had a consistent decrease in CD95 expression. Using different
antibodies, we failed to detect the plasma membrane form of its
ligand, CD95L, but we could see the intracellular presence of
that molecule in A301 cells and, to a lesser extent, in ACH-2
cells, but not in U937 or U1 cells. To confirm the cytofluori-
metric data and quantify the expression of CD95L at the RNA
level, we developed a quantitative competitive RT-PCR assay.
The HUT78 cell line had about 50 000 copies mRNA/1000 cells,
three times more after induction with a phorbol ester and
ionomycin. ACH-2 expressed about 400- (basal) or 10- (induced)
fold less CD95L mRNA than the parental cell line A301; U937
and U1 were below the limit of detection. In cells of lymphoid
origin (ACH-2) chronic HIV infection inhibits the expression of
CD95L, the phenomenon occurring at the transcriptional level.
In cells of monocytic origin (U1) the infection decreases the
plasma membrane expression of CD95. This suggests that HIV
could trigger different anti-apoptotic strategies which likely
depend upon the cell line which is infected. In monocytic cells
which act as a viral reservoir, the expression of the molecule
whose binding triggers apoptosis decreases, while in lymphoid
cells, capable of exerting cytotoxicity, the expression of a
molecule which induces apoptosis is reduced.
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1. Introduction
Infection with human immunode¢ciency virus type 1 (HIV-
1) causes a loss of T helper lymphocytes, which is crucial to
the development of the immunode¢ciency. The mechanism(s)
by which HIV-1 provokes death of CD4+ T cells has been
under investigation for many years. A fundamental issue is
whether HIV-1 primarily induces direct killing of infected cells
or indirectly causes death of uninfected bystander cells. Apop-
tosis of T cells plays an important role in the pathogenesis of
HIV infection [1^4], and correlates with the progression of
disease, as shown by many investigators who studied di¡erent
groups of patients, ranging from the earliest moments of
primary infection to the so-called long-term non-progressors
[5^8].
Among the large variety of molecules involved in this proc-
ess, members of the tumour necrosis factor (TNF) family such
as CD95 (APO-1/Fas) and its ligand (CD95L) have been ex-
tensively studied because of their capacity to trigger apoptosis
[9^11]. However, the role of CD95/CD95L interactions in de-
termining the increased tendency to undergo apoptosis in cells
from HIV+ subjects is far from being clear. In fact, although
it is known that up-regulation of CD95 expression during
HIV infection enhances the lymphocytes’ propensity to cell
death, di¡erent and contrasting reports exist on the expression
of CD95L in immune cells (reviewed in [12]). Many reasons,
mostly due to technical problems, may account for the dis-
crepancies regarding CD95L expression in di¡erent cell types
or in cells from HIV+ patients. Over the past years, di¡erent
groups have used anti-CD95L polyclonal rabbit antibodies
[13^15], which only recently have been shown to be unable
to detect cell surface CD95L when analysed by £ow cytometry
[16]. Similar problems arise with di¡erent monoclonal anti-
bodies (mAbs) directed to the plasma membrane form of
CD95L.
On the other hand, molecular biology techniques based
upon polymerase chain reaction (PCR) have been employed
in studies on cells from HIV+ patients, demonstrating a de-
crease in CD95L expression at the mRNA level [17]. How-
ever, the limitation of these techniques is that they are only
semiquantitative, and do not take into consideration the in-
trinsic variability of the type of analysis. In order to contrib-
ute to a better analysis of CD95L, we developed a sensitive
system to quantify the amount of CD95L mRNA using a
PCR-based competitive approach, comparing it with a classi-
cal, cyto£uorimetric approach performed using di¡erent com-
mercially available anti-CD95L mAbs.
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2. Materials and methods
2.1. Cell lines
The following cell lines of human origin were studied: A301, ACH-
2, U937, U1 and HUT78. The human ACH-2 and U1 chronically
HIV-infected cells derived from limiting dilution of cells surviving
acute in vitro infection with HIV-1 (HTLV-III/LAV) of the T cell
line A301 and the promonocytic cell line U937, respectively [18,19].
HUT78 cells derived from a human cutaneous T cell lymphoma which
expresses high levels of plasma membrane CD95L and is largely used
in studies on cytotoxicity via CD95 [20,21]). Cells were collected dur-
ing the log phase of growth, when viability was s 95%, and immedi-
ately used for the cyto£uorimetric analyses described below. In order
to increase CD95L expression, 1.5U106 cells were then resuspended in
1 ml of RPMI supplemented with 10% (v/v) FCS, 2 mM L-glutamine,
100 U/ml penicillin and 10 Wg/ml streptomycin and cultured in the
presence or in the absence of 3 ng/ml phorbol 12-myristate 13-acetate
(TPA) and 2 WM ionomycin (Ion) for di¡erent periods (up to 24 h).
Each experiment was repeated a minimum of four times, with only
negligible variations.
2.2. Flow cytometry
2.2.1. Phenotype analysis and quantitation of CD95 and CD95L
expression. Flow cytometric analysis was performed with £uoro-
chrome-labelled mAbs, according to standard methods [22]. Living
cells were identi¢ed on the basis of their physical characteristics (for-
ward and side scatter, i.e. FSC and SSC, respectively), and their
percentage, as assessed in parallel samples, was always s 95%. We
used anti-CD95 mAbs from Pharmingen (San Diego, CA, USA; clone
DX2, mouse IgG1,U directly conjugated with phycoerythrin, PE); for
the detection of CD95L, we used two di¡erent mAbs: clone Alf-2.1
(Caltag Lab., Burlingame, CA, USA, mouse IgG2a,U directly conju-
gated with PE) and clone NOK-1 (Pharmingen, mouse IgG1,U whose
binding was revealed by FITC-conjugated goat anti-mouse Ig, from
Becton Dickinson, San Jose, CA, USA). The anti-CD95L rabbit pol-
yclonal antibody C-20 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was also tested. Control samples were treated with control
rabbit IgG, and showed an unspeci¢c staining 6 0.2%. All samples
were treated with C-20 or control rabbit serum (from Pigei, Cavezzo,
Italy) for 45 min at 4‡C, followed by PE-conjugated goat anti-rabbit
IgG (Sigma, St. Louis, MO, USA) as the secondary reagent (40 min at
4‡C). For the analysis of CD95 and CD95L on the cell surface, cells
were incubated for 30 min at 4‡C with adequate amounts of mAbs,
washed twice and analysed. Intracellular staining of CD95L was per-
formed after ¢xation in 2% paraformaldehyde and permeabilisation of
cells with 0.5% Triton-X, according to standard methods [23]. A
FACScan (Becton Dickinson) £ow cytometer was used, as described
[24].
For the quantitation of CD95 and CD95L expression, samples were
immediately analysed after staining, and data acquired using a loga-
rithmic ampli¢cation of the £ow cytometer photomultiplier devoted to
collect the £uorescence from PE or FITC. Then, data were trans-
formed into a linear scale, as described elsewhere [25]. As CD95 or
CD95L was supposed to be expressed by almost all cells, to calculate
the changes in antigen expression, we took the linearised median value
from each sample and compared it with its adequate negative control
(i.e. the signal from the same cells stained with a PE- or FITC-labelled
irrelevant mAb of the same isotype). The di¡erence between these two
values, i.e. the relative £uorescence intensity (expressed in Fig. 1 by
the Greek letter v) indicates the number of linear channels represent-
ing the net £uorescence due to the binding of the mAb to its antigen.
Auto£uorescence from the cell populations we analysed was always
negligible, and of the same order (not shown).
2.3. RNA extraction and puri¢cation
Total RNA was puri¢ed from di¡erent cell lines with High Pure
RNA puri¢cation kit (Boehringer, Mannheim, Germany) according to
the procedure recommended by the supplier. RNA was resuspended
in 100 Wl of elution bu¡er. The total amount of RNA extracted from
HIV+ and HIV3 cells was always of the same order, i.e. 10^20 Wg/106
cells.
2.4. Construction of an RNA competitor for FasL
An RNA competitor for FasL mRNA was constructed carrying out
an internal deletion in a 259 bp region of DNA encoding the human
FasL gene. In brief, a 259 bp region, spanning the ¢rst exon, was
ampli¢ed with primers 60D (5P-GGGAATTCTGAGAAGAAG-
TAAAACCGTTTGCTG-3P) and 276R (5P-GGGGATCCGGTGG-
CAGCGGTAGTGGAG-3P), which bring a tail with EcoRI and Bam-
HI restriction sites, respectively. This fragment was then cloned in
pGEM-3Z; the recombinant plasmid obtained, named pFM3259,
was digested with ApaI and BglII, blunt-ended with Klenow fragment
and self-ligated; a deletion of 33 bp was obtained. One microgram of
this plasmid, named pFasL, was puri¢ed from transformed Escheri-
chia coli DH5K cells and digested with XbaI. Linearised pFasL was in
vitro transcribed using 40 U of T7 polymerase, in the presence of
rNTPs 1 mM, 40 mM Tris-HCl, 6 mM MgCl2, 10 mM DTT, 2 mM
spermidine and 0.5% Tween 20. The reaction was stopped by heating
at 70‡C for 15 min. The integrity of RNA was veri¢ed on 2% de-
naturing agarose gel. DNA used for transcription was eliminated by
digestion with 40 U Dnase-Rnase-free (Boehringer). A PCR without
previous reverse transcription was performed on serial dilutions of
transcribed RNA, to test for the presence of DNA contamination.
A ratio of about 300 000:1 was found between RNA and DNA.
DNA can thus be considered not capable of in£uencing the subse-
quent competitive RT-PCR. The concentration of puri¢ed RNA was
estimated by spectrophotometer evaluation and con¢rmed by end-
point dilution. The competitor was immediately divided into several
aliquots and stored at 380‡C.
2.5. Competitive RT-PCR
Before the reverse transcription reaction, 5 Wl of RNA from cells
(i.e. 500 ng of RNA), 5 Wl of competitor at various concentrations
(from a minimum of 1.75U103 to a maximum of 1.75U106 molecules
per tube), and primer 276R (5 pmol) were heated at 70‡ for 5 min and
immediately cooled on ice, to prevent formation of secondary struc-
tures. Then reverse transcription was performed at 42‡C for 45 min, in
the presence of dNTPs 400 WM, 50 mM Tris-HCl pH 8.3, 75 mM
KCl, 3 mM MgCl2, 10 mM DTT, 200 U MuMLV RT (Promega,
Madison, WI, USA), 40 U RNasin (Promega), 276R primer
200 nM, 5 Wl of RNA from cells and 5 Wl of competitor RNA at
various concentrations. The ¢nal volume of the reaction was 25 Wl.
After reverse transcription, MuMLV RT was inactivated by heating
at 95‡C for 5 min. The product of reverse transcription was used
directly for PCR, after addition of 25 Wl of 1UPCR bu¡er, containing
2.5 U of Taq polymerase (Promega), primers 60D and 276R 200 nM.
Ampli¢cation was carried out for 50 cycles in a Perkin Elmer Thermal
Cycler 9700. Each cycle consisted of 30 s denaturation at 94‡C, 35 s
annealing at 56‡C and 45 s extension at 72‡C. The ¢rst cycle was
preceded by 5 min denaturation at 94‡C and the last one was followed
by 7 min extension at 72‡C.
Ten Wl of PCR product was loaded on 0.6% LE/2.4% NuSieve
agarose gel (FMC) and run at 90 V for 40 min, stained with ethidium
bromide (EtBr) and analysed with a GelDoc 2,000 (Bio-Rad) video-
densitometer. The competitor band was observed as a lower 223 bp
band with respect to the 259 bp band of the wild type. The relative
intensity of the competitor band was corrected by a factor of 1.16, to
compensate for minor EtBr incorporation. Multiple reactions were
performed for the same sample, using increasing amounts of the com-
petitor molecules. The ratio between the lower and the upper bands
was linearly correlated with the input number of competitor molecules
(r2 always s 0.9), and the number of copies of wild type RNA was
calculated as described elsewhere [26].
A PCR without previous reverse transcription was always per-
formed to test for DNA contamination, and gave negative results.
2.6. Statistical analysis
To analyse the di¡erences in the £uorescence intensity of cells
stained with anti-CD95 mAbs we used unpaired, two-tailed Student’s
t-test. The same test was used to analyse di¡erences in the expression
of CD95L mRNA between control and infected lines; the paired t-test
was used to analyse the e¡ects of the treatment with TPA/Ion.
3. Results and discussion
Interactions between CD95 and CD95L have a crucial im-
portance in apoptotic phenomena, and, consequently, in sev-
eral pathologies including the infection by the virus that
causes AIDS [27]. In the past years, the expression and func-
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tion of CD95 have been widely studied. It is well known that
this molecule is expressed, and can increase its presence, in a
variety of conditions, including cell activation, cell prolifera-
tion, di¡erent viral infection, among others. We have studied
the plasma membrane expression of CD95 in HIV-infected
cell lines of lymphocytic (ACH-2) and monocytic (U1) origin,
and found that there is a consistent decrease of this molecule
in U1 (P6 0.01) but not in ACH-2 cells (Fig. 1). Functional
analyses indicate that, using a variety of stimuli, U1 have a
lesser tendency to undergo apoptosis than the parental line
Fig. 1. Cyto£uorimetric analysis of: (i) the plasma membrane expression of CD95 in parental (A301 and U937) and HIV-infected (ACH-2 and
U1) cell lines. K indicates negative controls. The analysis of the relative £uorescence intensity (v, related to the di¡erence in £uorescence chan-
nels between controls and the stained cells) shows that U1, but not ACH-2, cells have a consistent decrease in the expression of CD95; (ii) the
plasma membrane expression of CD95L in di¡erent cell lines, including HUT78, after induction with TPA/Ion. Two mAbs, NOK-1 and Alf-
2.1, were used. K indicates negative controls. In no case could we detect the plasma membrane form of CD95L; (iii) the intracellular presence
of CD95L in A301 and ACH-2 cells. K1 and K2 indicate the relative negative controls. Note that A301 cells have a higher £uorescence inten-
sity than ACH-2. One representative experiment out of four is shown.
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U937 (J. Pedrazzi et al., manuscript submitted). This is fully
consistent with a previous report, which showed that the via-
bility of U1 cells was not a¡ected by treatment with anti-
CD95 mAb, and they did not die of apoptosis [28]. Moreover,
although these cells expressed CD95 on the surface, TNF-K
was unable to up-regulate the expression of this molecule.
Interestingly, we could not extend this observation to ACH-
2 vs A301 cells. In fact, the HIV-infected cell line of lympho-
cytic origin had the same amount of CD95 as the uninfected,
parental line, but an increased tendency to undergo apoptosis
after di¡erent stimuli (submitted). Thus, HIV-infected cells of
di¡erent origin regulate, and likely use in a di¡erent manner,
a molecule that has a crucial importance in the induction of
apoptotic phenomena.
Less is clear concerning the role of the CD95/CD95L path-
way in HIV infection, and especially about the quantitative
expression of CD95L in di¡erent cells and models (reviewed
in [12]). Reports exist in the literature claiming that the CD95/
CD95L system is hyper-activated or hyper-expressed, and
highly responsible for the induction of apoptosis in cells
from HIV patients or in HIV-infected cell lines [15,27,29^
34]. Other reports go in the opposite direction, casting some
doubts on the role of that pathway, and in particular on the
hyper-expression of CD95L in HIV-infected cells [35,36].
Many discrepancies concerning the expression of CD95L
could be explained by the existence of problems related to
the antibodies used. Indeed, not only polyclonal [16] but
also mAbs exist that have a low capacity to detect the surface
expression of CD95L. In fact, we searched for the presence of
plasma membrane CD95L in a cell line which is known to
produce high amounts of CD95L and e⁄ciently kills CD95+
targets (i.e. HUT78) [21], as well as in HIV-infected cells
(ACH-2 and U1) and in their parental lines (A301 and
U937), but we failed to detect it using either two di¡erent
mAbs (NOK-1 or Alf-2.1, see Fig. 1) or polyclonal antibodies
(not shown). Recently, it was shown that, before degranula-
tion, CD95L can be stored in specialised secretory lysosomes
in both CD4+ and CD8+ T lymphocytes and natural killer
cells [37]. We thus analysed the amount of intracellular mol-
ecule by a £ow cytometric approach, and indeed could detect
the presence of CD95L either in A301 or in its HIV+ clone,
ACH-2. The latter cells, however, had a slightly lower amount
of molecule, as assessed in several repeated experiments (Fig.
1). To con¢rm the cyto£uorimetric data, we decided to quan-
tify the expression of CD95L at the RNA level using a PCR-
based approach.
Fig. 2. Upper part: Strategy for the construction of a mRNA com-
petitor for CD95L. See text for details. Middle part: Typical exam-
ple of quantitative competitive RT-PCR with scalar amounts of
competitor (C), i.e. 35^1750U104 copies/tube, and a ¢xed dose of
wild type RNA (WT). MW: molecular weight marker (PX174 di-
gested with HaeIII); two values are indicated in the left part (310
and 234 Da). Lower part: Kinetics of the induction of CD95L
mRNA in HUT78 cells stimulated with TPA/Ion.
Fig. 3. Upper part: Representative examples of quantitative compet-
itive RT-PCR in A301 (upper picture) and ACH-2 cells (lower pic-
ture). Numbers indicate the scalar amounts of competitor (C), i.e.
17.5^1750U103 copies/tube, co-ampli¢ed with the wild type RNA
(WT). Molecular weight marker as in Fig. 2. Lower panel: The
graphics show that HIV-infected ACH-2 cells have a decreased ex-
pression of CD95L in comparison with the parental line A301 either
in basal conditions or after stimulation with TPA/Ion.
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PCR analyses performed by others, coupled with cyto£uori-
metric analyses, have shown a decreased CD95L expression in
cells from HIV+ individuals [17]. However, PCR assays pro-
vide results which are only semiquantitative, and do not take
into account the intrinsic variability of the type of analysis. A
commonly experienced problem with PCR is indeed its poor
reproducibility, even under the most controlled experimental
conditions. Minor di¡erences in the e⁄ciency of ampli¢cation
result in large di¡erences in the product yield, especially when
the amount of initial template is low. Assays based on com-
petitive PCR are much more precise for the quantitation of a
given gene or for its expression. In principle, by this method
two DNA species (wild type and competitor) compete for
PCR ampli¢cation. Since results are calculated from the ¢nal
wild type/competitor ratio, any variable a¡ecting the rate of
PCR ampli¢cation has no e¡ect on the accuracy of the ratio
measurement. The same concept can be applied for measure-
ments at the mRNA level, when an RNA competitor is used
and is present in the reaction tube from the beginning of the
reaction, i.e. the retrotranscription phase. In all cases, even
large variations in the experimental conditions (number of
PCR cycles, sample volumes and extracted DNA or RNA
quality) do not interfere with the precision of the measure-
ment of the wild type/competitor ratio [38]. For all these rea-
sons, we thought it worth while to develop an approach to
rapidly and precisely analyse CD95L expression, by using
quantitative competitive RT-PCR, and constructed an RNA
competitor using the strategy described above (see Fig. 2,
upper part). The minimum level of detection, considering
that the e⁄ciency of extraction of RNA from cells was sat-
isfactory and constant (i.e. in the order of 10^20 Wg/106 cells,
for all lines), was about 2000 copies CD95L mRNA/106 cells.
We ¢rst analysed the expression of CD95L in a classical cell
line widely used as e¡ector for exerting CD95L-mediated cy-
totoxicity, i.e. HUT78. Fig. 2, middle part, shows a typical
example of competitive PCR analysis. It has to be underlined
that with this approach the calculation of the copies of wild
type RNA uses the ratio between the two bands in each single
lane, and not their relative intensity in di¡erent lanes. This
allows a precise analysis even in the case that the reactions
were not optimal in a given PCR tube, as retrotranscription
and ampli¢cation are identical for either the wild type or the
competitor, both present in the same tube. Fig. 2, lower part,
reports the kinetics of induction of CD95L mRNA, showing
that the expression of mRNA was maximal after 4 h of stim-
ulation with TPA/Ion, as HUT78 could express about 150 000
copies/1000 cells. This amount decreased after a few hours to
basal levels (about 40 000 copies), and decreased again in 24 h.
We then studied the expression of CD95L in HIV+ cell
lines. U937 and its derived clone, U1, had undetectable levels
of CD95L (not shown). In contrast, in agreement with the
cyto£uorimetric observations, ACH-2 expressed signi¢cantly
lower levels of CD95L mRNA than the parental line A301,
either in basal conditions or after stimulation (Fig. 3). The
increase of mRNA after treatment with TPA/Ion was always
signi¢cant (P6 0.01). Experiments were repeated a minimum
of four times, indicating that although very few copies of
CD95L per cell were present in comparison with the
HUT78 cell line, their presence could be quanti¢ed either in
basal conditions or after stimulation with TPA/Ion. The dif-
ference between HIV+ and uninfected cells was statistically
signi¢cant (P6 0.01). It has to be underlined that RNA was
extracted from all cells, and thus the low number of copies we
found per cell represents the mean from the entire population,
whose single components have likely di¡erent amounts of
CD95L mRNA, for example because of di¡erences in the
cell cycle. Further studies on synchronised cells are required
to clarify this point.
In conclusion, the main results of this study can be simply
summarised as follows: (i) in a cell line of lymphoid origin
such as ACH-2 chronic infection with HIV inhibits the ex-
pression of CD95L, the phenomenon occurring at the tran-
scriptional level ; (ii) in cells of monocytic origin such as U1
the infection decreases the plasma membrane expression of
CD95. Studies at the protein and mRNA levels with new
RNA competitors are under way to ascertain whether the
reduced expression of CD95 on the plasma membrane is as-
sociated with changes in the production of the CD95 soluble
form.
The data we present here explore the delicate balance be-
tween mechanisms triggered by the virus to favour its repli-
cation and survival, and those triggered by the immune system
to cope with the infection. HIV regulates apoptosis in a com-
plex way, requiring live, functional cells for its replication.
Some of its products can either protect from or induce apop-
tosis [39,40]. The chronically infected cell lines we used are in
a sort of steady state, in which a dynamic equilibrium likely
exists between the production of pro- and anti-apoptotic fac-
tors of either cellular and viral origin. As the rate of sponta-
neous apoptosis in HIV+ cell lines was extremely low (not
shown), and cells proliferate quite well, it is likely that the
balance leans towards the side of anti-apoptotic mechanisms.
Therefore, on the one hand, it could be hypothesised that HIV
is capable of triggering several, co-ordinated strategies which
likely depend upon the cell line which is infected, with the
ultimate aim of reducing apoptosis and favouring viral pro-
duction. Indeed, in monocytic cells which act as a reservoir,
HIV down-regulates the expression of a molecule whose acti-
vation induces apoptosis, i.e. CD95. In cells of lymphocytic
origin, capable of exerting cytotoxic responses, it could be
convenient to down-regulate the expression of a molecule
which induces apoptosis, i.e. CD95L. On the other hand, as-
suming that the model we studied has some similarities with
the situation present in vivo during chronic infection, para-
doxically the down-regulation of CD95L could be favourable
for the host because activated, cytotoxic T cells, expressing
CD95, can be killed by CD95L+ CD4+ lymphocytes [41].
Even if further studies are needed to clarify the role of
CD95/CD95L interactions in vivo, this report shows that in
the in vitro models of chronic HIV infection a down-regula-
tion of the CD95/CD95L pathway exists which may favour
viral production.
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